Nexalin Secures $750K Direct Offering and $15M Equity Facility to Fund Pivotal Trial
NXL is trading near its 52-week low of $0.305 (8.4% above the low) on light trading volume (0.2× avg).
Summary
Nexalin Technology raised $750,000 in a direct offering at $0.31 per share with warrants, and entered a $15 million committed equity facility, providing critical funding amid going concern and Nasdaq delisting risks.
Key Events · Financing and Capital Events · NXL
-
Direct Offering of $750K
A single accredited investor purchased 2,419,354 shares at $0.31 per share, yielding $750,000 in gross proceeds. The price reflects a 7% discount to the last reported sale price of $0.3333 on August 18, 2026.
-
Warrants in Private Placement
The investor received warrants to purchase up to 1,209,677 shares at $0.50 per share, exercisable immediately and expiring in one year. If fully exercised for cash, Nexalin would receive an additional $604,839.
-
$15M Committed Equity Facility
Concurrently, Nexalin entered an Any Market Purchase Agreement (AMPA) allowing it to sell up to $15 million of shares to the investor at a 3-8% discount to market prices. A 2% commitment fee ($300,000) is payable, increasing to 3% if delisted within 30 business days.
-
Nasdaq Delisting Risk
The offering is intended to help address Nasdaq's minimum stockholders' equity deficiency, but net proceeds of $657,000 will not raise equity to the required $2.5 million. A Nasdaq Hearings Panel hearing is scheduled for September 1, 2026.
Analysis · NXL · Industrial Applications And Services
A $750,000 direct offering of 2,419,354 shares at $0.31 per share—a 7% discount to the last reported sale price of $0.3333 on August 18, 2026—provides immediate capital for Nexalin Technology. The deal includes warrants to purchase an additional 1,209,677 shares at $0.50 per share, and a concurrent $15 million committed equity facility (AMPA) that allows the company to sell shares at a 3-8% discount to market. This financing is critical for Nexalin, which has a going concern warning, only $1.0 million in cash as of June 30, 2026, and faces Nasdaq delisting proceedings. Proceeds will fund the HALO Clarity pivotal clinical trial and regulatory activities, but the offering alone will not restore compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million. The AMPA provides potential future capital but is contingent on maintaining Nasdaq listing, which is uncertain given the September 1, 2026 hearing.
At the time of this filing, NXL was trading at $0.33 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $0.31 to $2.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.